Roche Aims to Capitalize on Obesity-Drug Market as It Seeks Recovery Amid Sector Turmoil

Investors who have been enduring a turbulent ride since Malin's flotation in March 2015, now face a potential end to the uncertainty as Roche eyes a recovery in the obesity-drugs market. Roche, previously underperforming and grappling with declining sales of its COVID-19 test kits and drug candidate failures, has made a significant move this year by acquiring Carmot for up to $3.1 billion.

This acquisition comes as the obesity-drugs market is projected to grow significantly, reaching an estimated $200 billion by 2031. The wider pharmaceutical sector, meanwhile, has been dealing with the repercussions of Donald Trump's re-election and the proposed appointment of an anti-vaccine activist as his health secretary, which has led to a further downturn in stock prices

Brasil Últimas Notícias, Brasil Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

Malin Corporation Shares Jump 37% on Roche Acquisition of PoseidaMalin Corporation, a Dublin-based life sciences investment firm, experienced a significant rise in its share price following the news that Roche, a Swiss pharmaceuticals giant, has agreed to acquire Poseida, a Nasdaq-listed biopharma company in which Malin holds a 12% stake, for up to $1.5 billion.
Fonte: IrishTimes - 🏆 3. / 98 Consulte Mais informação »